LeuprolideGnRH agonist
Leuprolide, also called leuprorelin, suppresses reproductive hormones after an initial stimulating phase. Different products use that effect for different conditions, and their schedules and indications are not interchangeable.
What is Leuprolide?
Leuprolide, also called leuprorelin, is a GnRH agonist used in product-specific settings such as prostate cancer, endometriosis, fibroids and central precocious puberty. These indications require different clinical contexts. 1 2 3
How it works
Sustained GnRH receptor stimulation first raises and then suppresses pituitary gonadotropin signalling, lowering testosterone or oestrogen. The initial rise is known as a hormonal flare. 2 3
Effects studied
Sex-hormone suppression
Treatment aims differ by diagnosis: suppressing a hormone-dependent cancer, managing a gynaecological condition or controlling early puberty. Evidence from one population should not be transferred automatically to another.
Evidence: Population- and product-specific studies and labels. 1 2 3
What does the evidence show?
Condition-specific evidence and prescribing-information leads
A sustained signal changes pituitary behaviour
Leuprolide is a GnRH agonist. With sustained exposure, the pituitary becomes less responsive and releases less LH and FSH, reducing downstream sex hormones. Before suppression develops, a temporary increase can occur, which is why the initial phase matters in some clinical settings.
Different goals use the same pathway
In prostate-cancer care, treatment may aim to reduce androgen stimulation. In gynaecology, temporary suppression may be used for conditions such as endometriosis or fibroids. Paediatric products can address central precocious puberty. Each use involves different patients, outcomes and decisions about benefits and risks, so evidence from these groups needs to be considered separately.
The product is part of the intervention
Depot formulations release the medicine over different periods, and product-specific indications vary. A trial of one preparation in one condition cannot be read as proof for every leuprolide product. The retained references illustrate both paediatric hormone-suppression research and separate prescribing information. 1 2 3
What lowering hormones can cost
Bone loss, hot flushes, sexual symptoms and changes in mood or metabolic health can be relevant, depending on the patient and treatment duration. Some care plans include additional measures to manage these consequences. The condition and the person’s circumstances determine the balance: suppressing sex hormones is neither uniformly helpful nor uniformly harmful.
Safety & status
Bone health, hot flushes, sexual effects, mood and metabolic changes can be relevant. Formulation and duration influence the safety and monitoring context. 2 3
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Why are there different leuprolide products?
Delivery duration and approved uses vary; the active ingredient alone does not specify the treatment. 2 3
Is the initial hormone rise the intended long-term effect?
No. The longer-term goal is suppression after pituitary downregulation. 2
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.